J Biol Chem, Vol. 274, Issue 39, 27891-27897, September 24, 1999
Distinct Roles of Thioredoxin in the Cytoplasm and in the
Nucleus
A TWO-STEP MECHANISM OF REDOX REGULATION OF TRANSCRIPTION FACTOR
NF-
B*
Kiichi
Hirota
,
Miyahiko
Murata§,
Yoshifumi
Sachi¶,
Hajime
Nakamura¶,
Junko
Takeuchi
,
Kenjiro
Mori
, and
Junji
Yodoi¶
From the
Department of Anesthesia, Kyoto University
Hospital, the § Department of Integrative Brain Science,
Graduate School of Medicine, and the ¶ Department of Biological
Responses, Institute for Virus Research, Kyoto University,
53 Shogoin-Kawaharacho, Sakyo-Ku, Kyoto, 606-01, Japan
 |
ABSTRACT |
Oxidative stresses such as UV irradiation to
mammalian cells triggers a variety of oxistress responses including
activation of transcription factors. Recently, activation of nuclear
factor-
B (NF-
B) has been shown to be under oxidoreduction (redox)
regulation controlled by thioredoxin (TRX), which is one of major
endogenous redox-regulating molecules with thiol reducing activity. In
order to elucidate where in the cellular compartment TRX participates in NF-
B regulation, we investigated the intracellular localization of TRX. UVB irradiation induced translocation of TRX from the cytoplasm
into the nucleus. In our in vitro diamide-induced
cross-linking study, we showed that TRX can associate directly with
NF-
B p50. Overexpression of wild-type TRX suppressed induction of
luciferase activity under NF-
B-binding sites in response to UV
irradiation compared with the mock transfectant. In contrast,
overexpression of nuclear-targeted TRX enhanced the luciferase
activity. Thus, TRX seems to play dual and opposing roles in the
regulation of NF-
B. In the cytoplasm, it interferes with the signals
to I
B kinases and blocks the degradation of I
B. In the nucleus,
however, TRX enhances NF-
B transcriptional activities by enhancing
its ability to bind DNA. This two-step TRX-dependent
regulation of the NF-
B complex may be a novel activation mechanism
of redox-sensitive transcription factors.
 |
INTRODUCTION |
Exposure of mammalian cells to UV light induces various responses
in cells (1, 2). Many of the cellular responses can be triggered by a
change in intracellular redox state resulting in cytotoxicity or stress
to cells (2, 3). Oxidative stress caused by exposure to UV light,
hydrogen peroxide, heavy metals, and inflammatory cytokines can elicit
not only "negative" responses such as cell death but also
"positive" responses including cell proliferation and activation
(1, 4). There is a growing body of evidence that shows that the
intracellular redox state can modulate various kinds of gene
expression. TRX1 is known to
be one such intracellular redox regulator
(5-8). TRX is a small, ubiquitous protein with two redox-active
half-cysteine residues in its catalytic active center, having the
consensus amino acid sequence -Cys-Gly-Pro-Cys- (9). The protein exists either in a reduced form with a dithiol or in an oxidized form, in
which the half-cystine residues form an intramolecular disulfide bridge. TRX participates in redox reactions by reversible oxidation of
its active center dithiol to a disulfide and catalyzes
dithiol-disulfide exchange reactions (10) involving many
thiol-dependent cellular processes, including gene
expression and signal transduction. Human TRX was originally cloned as
a soluble factor named adult T-cell leukemia-derived factor, which was
purified from the conditioned medium of human T-cell lymphotrophic
virus-I-transformed CD4+ T-cell line, ATL-2 (11-14).
The transcription factors, NF-
B, as well as activating factor 1 (AP-1), execute important roles in immune function, inflammatory response, cell adhesion, and growth control (15-17). AP-1 was shown to
be an antioxidant-responsive transcription factor (1, 18, 19).
Transient overexpression of TRX can stimulate
AP-1-dependent transcription (8, 20, 21). We showed that
TRX, which is mainly in the cytoplasm, quickly translocates into the
nucleus in response to phorbol 12-myristate 13-acetate (PMA) and
activates AP-1 transcription activity by direct association with an
intranuclear redox factor, Ref-1 (8). In the case of NF-
B, however,
there seems to be some controversy on the redox regulation of its
activation. NF-
B is stored as an inactive cytoplasmic complex in
association with I
B. When activation signals reach the I
B kinase
complex (22-27), I
B are phosphorylated by I
B kinases to be
degraded and dissociated from NF-
B, and this free NF-
B complex
translocates from the cytoplasm into the nucleus (17, 28). It is
suggested that reactive oxygen intermediates (ROIs), which are
generated in the cells, act as second messenger molecules as follows:
cytokines such as TNF
binding its specific receptor causes oxidative
stress or an increase in the ROI concentration in cells (1). Treatment of cells with radical scavengers, such as
N-acetyl-L-cysteine and pyrrolidine
dithiocarbamate, as well as transient overexpression of TRX inhibited
nuclear translocation and transactivation of NF-
B (20, 29).
Once translocated into the intranuclear compartment, however, the redox
environment seems to be quite important for NF-
B activity. DNA
binding activity of NF-
B is shown to be under redox regulation
through the modulation of cysteines (5, 20). Like c-Jun, c-Fos (30),
Myb (31), p53 (32), PEBP2 (6), and nuclear receptors such as
glucocorticoid receptor (7, 33) and estrogen receptor (34), NF-
B
component, p50, and p65/Rel-A have a well conserved cysteine (Cys) in
its DNA-binding loops (35, 36). An in vitro study (37)
showed that an alkylating agent, N-ethylmaleimide,
irreversibly inhibited the DNA binding activity of NF-
B; NF-
B was
inhibited by modulating its conserved Cys residue, using diamide, a
sulfhydryl (SH)-oxidizing agent. This inhibition was reversed by
treatment with reducing agents such as 2-mercaptoethanol,
dithiothreitol, and recombinant human TRX (5, 38). Moreover, there is a
report that transient overexpression of human TRX in COS1 and Jurkat
T-cell augments gene expression from human immunodeficiency virus, type
I-long terminal repeat (39). TRX, thus, is suggested to be a candidate
for the endogenous molecules that play in redox regulation of gene
expression of transcription factor NF-
B. The main aim of this paper
is to clarify where and how TRX regulates a transcription factor,
NF-
B complex, which translocates from cytosol to nucleus, and to
elucidate a dynamic role of TRX on redox regulation of transcription in
cells. For this purpose, we investigated the subcellular localization of TRX after stimulations including UVB irradiation and TNF
treatment and a possibility of direct association between NF-
B and
TRX in the nucleus. Our data indicate that TRX translocates from the cytoplasm into the nucleus and translocated TRX potentiates
NF-
B-dependent transcription. Moreover, direct
association between TRX and NF-
B in the nucleus was suggested by
in vitro cross-linking assay.
 |
EXPERIMENTAL PROCEDURES |
Cells and Cell Culture--
Transformed human keratinocytes,
established from human squamous cell carcinoma of skin, HSC-1, were a
gift from Dr. Y. Kondo (40). HSC-1, NIH3T3, and HeLa cells were
cultured in Dulbecco's modified Eagle's medium (Life Technologies,
Inc.) supplemented with 10% fetal calf serum, penicillin (100 units/ml), and streptomycin (100 µg/ml) at 95% humidity in 5%
CO2 in air at 37 °C.
Reagents--
Human tumor necrosis factor-
(TNF
) was from
Life Technologies, Inc. Anti-human TRX monoclonal antibodies, 11-mAb
and 21-mAb (41), were established and provided by FujiRebio, Inc.
(Tokyo, Japan). Anti-NF-
B p50 (NL5), anti-NF-
B p65 (A), and
anti-I
B
(C21) polyclonal antibody were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
UV Light Irradiation--
Cells were plated on chamber slides
(Nunc Inc., Naperville, IL). The culture media were replaced with
prewarmed phosphate-buffered saline (PBS), and the cells were exposed
to an UVB source (UVP Inc., Upland, CA). After exposure, cells were
incubated with culture media at 37 °C.
Plasmids--
Mutagenesis of human TRX was performed by a
polymerase chain reaction-based technique (8) and subcloned into
BamHI-SalI-cut pBluescript II SK+ plasmid
(pBSII-TRX). Expression vectors for TRX, pcDNA3-TRX-wt and
pcDNA3-TRX-dm, were made by inserting
BamHI-XhoI fragment from pBSII-TRX plasmids into
BamHI-XhoI-cut pcDNA3 (Invitrogen Corp., San
Diego, CA). An expression vector, pCMX-GAL4-TRX-wt, was described
previously (8). pcDNA3-anti-TRX was made by inserting BamHI-HindIII fragment from pcdSR
TRX plasmid
(8) into BamHI-HindIII-cut pcDNA3.
Transfection--
The expression plasmids were introduced into
the cells by the use of LipofectAMINE reagent (Life Technologies,
Inc.), following the protocol previously described (8).
Indirect Immunofluorescence Cell Staining--
Indirect
immunofluorescence cell staining was performed following the protocol
previously described. Briefly, cells were fixed with 3.7%
paraformaldehyde in PBS containing 10% fetal calf serum for 20 min at
room temperature, followed by permeabilization for 10 min using 0.2%
(w/v) Triton X-100 in PBS. After incubation with primary antibodies
(for TRX, monoclonal 11-mAb; for NF-
B p50 or p65, polyclonal
antibody) for 1 h at room temperature. The slides then were
incubated for 1 h with a secondary antibody as follows:
fluorescein isothiocyanate-conjugated sheep anti-mouse IgG (Amersham
Pharmacia Biotech) for TRX, or tetramethylrhodamine isothiocyanate-conjugated goat anti-rabbit IgG (Sigma) for NF-
B p50
or p65. Slides with stained cells were mounted in 90% glycerol with 1 mg/ml p-phenylenediamine and examined with a confocal
microscope, MRC-1024 (Bio-Rad).
Expression of Recombinant Proteins in Bacteria--
Human TRX
recombinant proteins were expressed in Escherichia coli as
the N-terminal fused form with hexahistidine (6xHis) tag using the
pQE30 expression plasmids (Qiagen) essentially following the protocol
described previously (8). Truncated human NF-
B p50 DNA-binding
domain (residues 35-381) was expressed based on the pQE-p50 as a
6xHis-tagged protein by use of the same protocol as that used for the
expression of TRX.
Western Blot Analysis of Nuclear Fraction of HSC-1--
Crude
nuclear cell extracts were prepared as described (42). Each fraction
was applied to a 15% SDS-PAGE and electrophoresed. After
electroblotting, the polyvinylidene difluoride membrane (Millipore,
Bedford, MA) was treated with 5% (w/v) skim milk in TBS-T (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.5% Tween
20) and incubated with antigen-specific antibodies against human TRX, followed by incubation with peroxidase-conjugated anti-mouse IgG (Amersham Pharmacia Biotech). The epitope was visualized with an ECL
Western blot detection kit (Amersham Pharmacia Biotech). The amount of
TRX in each sample was estimated by analysis of the density of each
band, using a computerized densitometer (PDI Analyzer; ToYoBo, Tokyo, Japan).
In Vitro Disulfide Cross-linking Interaction Assay--
In the
cross-linking assay, 6xHis-TRXs (100 ng) and 6xHis-p50 (200 ng) were
incubated for 30 min at room temperature with 1 mM
dithiothreitol (8). Then they were mixed and incubated in the presence
of 10 mM diamide for 30 min at room temperature in 20 µl
of PBS, pH 7.3. The reaction mixture was denatured for 5 min at
90 °C in dissociation buffer with or without 2-mercaptoethanol (1%). Each mixture was applied to a 15% SDS-PAGE and electrophoresed. Epitopes were detected by Western blot.
Insulin-reducing Assay--
To estimate the reducing activity of
TRX, an insulin-reducing assay was performed according to a previous
report (41). Briefly, yeast TRX reductase was provided by Oriental
Yeast Co. Ltd. (Tokyo, Japan) and can reduce mammalian TRX. The
decrease in absorbance at 340 nm was recorded by use of a THERMOMAX
microplate reader (Molecular Devices) to detect maximal NADPH
consumption rate (Vmax, millioptical density at
340 nm/min). As a control, samples were incubated with the reaction
mixture without insulin. Each value was calculated according to a
method previously reported. The calculated values were compared with
the standard curve for rTRX (100-1200 ng/ml) to obtain quantitative
determinations of the absolute amounts of TRX.
Reporter Assay--
A phagemid vector pNF-
B-luciferase, which
contains five copies of
B-binding motif of the murine immunoglobulin
light chain enhancer, was purchased from Stratagene, La Jolla, CA.
HeLa cells were plated in 6-well plates at a density of 5 × 105 cells per well. The expression plasmids were introduced
into the cells using LipofectAMINE reagent. In each transfection, 1 µg of the pcDNA3-TRX-wt or pCMX-GAL4-TRX-wt expression plasmid, 1 µg of pNF-
B-Luc, and 1 µg of pSV-
-galactosidase (Promega
Corp., Madison, WI) as an internal control were used. Total amounts of DNA were adjusted to 3 µg with pcDNA3. After incubation at
16 h, cells were irradiated with 400 J/m2 of UVB and
were kept for 12 h or incubated with recombinant human TNF
for
12 h. Then the cells were harvested, and luciferase activity was
determined using a commercial assay system (Promega) with a
luminometer, Lumat LB9507 (Berthold, GmbH & Co. KG, Bad Wildbad, Germany). The relative fold induction of luciferase activity was calculated by normalizing to the
-galactosidase activity.
 |
RESULTS |
UVB-induced Translocation of TRX from the Cytoplasm into the
Nucleus in Association with NF-
B--
As a step toward dissecting
the roles of TRX in early stage of UV responses, we examined
intracellular locations of TRX after UV exposure.
Transformed human keratinocytes, HSC-1 cells, were stained using an
immunofluorescence method with 11-mAb raised against human TRX. In
control cells without UVB irradiation, TRX was stained mainly in the
cytoplasm (Fig. 1A), whereas
after 1 h exposure to 400 J/m2 UVB, most of the
fluorescence translocated into the nucleus (Fig. 1B). Under
the same conditions, nuclear translocation of NF-
B p65/RelA was also
observed (Fig. 1, C and D). In contrast to the case of RelA subunit, NF-
B p50 was localized in the nucleus and remained there even after UVB irradiation (Fig. 1, E and
F). The UV-induced translocation of TRX was observed also in
HeLa cells (Fig. 1, G and H). Similar
translocation patterns were detected by use of another monoclonal
antibody, 21-mAb, which may recognize a different epitope on human TRX
(data not shown).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 1.
Confocal microscopic analysis of the
UVB-induced nuclear translocation of TRX and
NF- B in HSC-1 and HeLa cells. A and
B, immunostaining of TRX in HSC-1 cells. C and
D, immunostaining of NF- B p65 in HSC-1 cells.
E and F, immunostaining of NF- B p50 in HSC-1
cells. G and H, immunostaining of TRX in HeLa
cells. Cells were stained before (left panel) and 1 h
after (right panel) UVB irradiation (400 J/m2).
Shown are cells from one of two independent experiments.
|
|
To quantify the subcellular TRX after UVB irradiation, cytoplasmic and
nuclear extracts of HSC-1 cells were fractionated and analyzed by
Western blot analysis. In agreement with the results of the
immunofluorescence staining, the amount of TRX in the nuclear fraction
extracted 1 h after UVB irradiation was increased by about 4-fold
(Fig. 2). The total amount of
intracellular TRX was unchanged 1 h after irradiation (data not
shown).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
Western blotting analysis of subcellular
fractionation in HSC-1 cells. Nuclear extracts (30 µg/lane) of
HSC-1 cells were harvested at the indicated time after UVB irradiation.
Samples were resolved on 15% SDS-PAGE and analyzed by Western blot
analysis using 11-mAb, the monoclonal antibody raised against human
TRX.
|
|
TNF
Treatment Also Translocates TRX into the Nucleus--
Next,
we examined whether stimulation or treatment other than UV irradiation
could translocate TRX into the nucleus. TNF
is one of
pro-inflammatory cytokines and is known to be a potent NF-
B
activator. It is reported that formation of ROIs is crucial in this
process (43). As shown in Fig. 3, TNF
treatment (100 ng/ml) resulted in the translocation of TRX from the
cytoplasm into the nucleus in HeLa cells no later than 1 h after
the treatment. As reported previously PMA also translocated TRX
(8).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 3.
Confocal microscopic analysis of the PMA- and
TNF -induced nuclear translocation of TRX in
HeLa cells. TRX was immunostained in HeLa cells using 11-mAb. Cell
were labeled 1 h after (A) PMA (50 ng/ml) and
(B) TNF (100 ng/ml) treatment.
|
|
Direct Association between TRX and the NF-
B p50 Component by in
Vitro Disulfide Cross-linking--
As we and others (8, 9, 44, 45)
have shown previously, an oxidoreductase, TRX, forms an intermediate
with various target molecules through disulfide linkage. To dissect
further the detail of redox regulation of NF-
B, we examined direct
association between TRX and NF-
B in in vitro systems. We
reasoned that it would be possible to trap the transient physical
association using cross-linking reagent(s) such as diamide, which
converts free sulfhydryls to disulfides by cysteine oxidation (8, 9). In order to determine which of the five cysteines in TRX is responsible for intermolecular disulfide bond formation, TRX mutants, which contained cysteines-to-serines or cysteine-to-alanine substitution(s), were purified as the hexahistidine (6xHis)-tagged form. A series of
experiments was performed with the 6xHis-tagged NF-
B p50 and mutants
of TRX. It is known that TRX-(C62S/C69S/C73S) retains its reducing
activity (46). Wild-type or mutant recombinant TRX proteins were
incubated with recombinant NF-
B-p50 DNA-binding domain, and then
their migration patterns were analyzed. Antibodies against NF-
B p50
(Fig. 4, 4th and
8th lanes) and TRX (data not shown) recognized
the same extra bands migrating around 50 kDa in the lanes of TRX-wt and
TRX-(C62/69/73S) only under oxidizing conditions.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
TRX associates with
NF- B, p50 DNA-binding domain through the
redox-active cysteines in vitro. Wild
(wt) and mutant (C62S/C69S/C73S) recombinant TRX (200 ng)
were incubated with or without NF- B p50 (100 ng) in the presence of
diamide (10 mM). After incubation, the complexes were
resolved by electrophoresis under reducing or oxidizing conditions and
detected by an anti-NF- B, p50 (NL5) antibody. 2-ME,
2-mercaptoethanol.
|
|
Establishment of Nuclear-targeted TRX--
In order to understand
intranuclear roles of TRX, we constructed nuclear-targeted expression
vector of TRX (8). TRX lacks an authentic basic nuclear localization
signal amino acid sequence (47, 48). To prepare nuclear-targeted TRX,
we made a fusion construct with yeast GAL4 DNA-binding domain (amino
acids 1-147), which has a strong nuclear localization signal amino
acid sequence and human TRX as pCMX-GAL4-TRX-wt. Because anti-human TRX
monoclonal antibody, 11-mAb, does not recognize mouse TRX (41), it is
possible to trace the intracellular localization of the overexpressed
TRX in NIH3T3 cells with this antibody by immunofluorescent method. At
24 h after transfection of plasmids, immunofluorescent staining showed that human wild-type TRX dominantly existed in the cytoplasm (Fig. 5A) and translocated
into the nucleus after UVB irradiation (Fig. 5B); in
contrast, GAL4-TRX-wt existed in the nucleus without any treatment
(Fig. 5C) and remained in the nucleus after irradiation (data not shown). To evaluate the function of fusion construct of
GAL4-TRX, the TRX activity in transfected cells was analyzed by insulin
degradation assay. GAL4-TRX-wt-transfected NIH3T3 cells and TRX-wt
showed 1.76- and 1.83-fold increase in TRX activity over
mock-transfected cells (Table I).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Confocal microscopic analysis of
intracellular localization of overexpressed TRX of various types in
NIH3T3 cells. NIH3T3 cells were transfected with pcDNA3-TRX-wt
(A), or pCMX-GAL4-TRX-wt (B), or plasmid
(C). Cells were stained using the 11-mAb at 16 h after
transfection. A and C, without any treatment;
B, 1 h after UVB irradiation.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
The TRX activity in the transfected NIH3T3 cells
The activity in the transfected NIH3T3 cells was determined by insulin
reducing assay. NIH3T3 cells were transiently transfected with the
plasmid indicated. The efficiency of transfection was more than 80% as
judged by expression of green fluorescence protein. 24 h after
transfection, cells were harvested and subjected to insulin reducing
assay as described under "Experimental Procedures." Data
(micrograms/mg of protein) were expressed as the absolute amount of TRX
per mg of total protein. Results are means of duplicate determinations
of a single experiment and are representative of three similar
experiments.
|
|
NF-
B Activation by Intranuclear Overexpression of TRX in
UVB-irradiated HeLa Cells--
Next we examined the intracellular role
of TRX on transactivation of NF-
B. HeLa cells were transiently
cotransfected with a 5x-
B-luciferase reporter gene and various TRX
expression plasmids. In Fig. 6,
overexpression of wild-type TRX suppressed
NF-
B-dependent luciferase gene activity elicited by UVB
irradiation compared with mock transfection in
dose-dependent manner of pcDNA3-TRX-wt. In sharp
contrast, overexpression of nuclear-targeted GAL4-TRX-wt enhanced the
luciferase activity. Overexpression of Ref-1 also enhanced the
luciferase activity although this enhancement was not significant.
TRX-dm, which does not have reducing activity, had only a marginal
effect.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
Intranuclear overexpression of TRX induces
NF- B-dependent reporter gene
activity. A, influence of overexpression of various
endogenous redox molecules on the NF- B-mediated transcription.
NAC, N-acetyl-L-cysteine. HeLa cells
were transiently cotransfected with a 5× B-luciferase reporter gene
plasmid (1 µg) and expression vectors (1 µg) or pcDNA3 plasmid
as control (1 µg) with 0.5 µg of pSV- -galactosidase. Cells were
harvested at 12 h after irradiation. Luciferase activities were
determined and normalized on the basis of -galactosidase expression
(8). The results are the means (mean ± S.D.) of three experiments
(each done in duplicate) and presented as fold increases in luciferase
activity over the base line seen with the mock transfectant without
treatment. B, dose-dependent effect of TRX on
the NF- B-mediated reporter gene expression. Total amount of plasmid
was adjusted 3.5 µg with pcDNA3 plasmid.
|
|
Requirement of TRX in NF-
B-mediated Transcription--
Although
a targeted disruption of mouse TRX gene has recently been reported by
us (49), homozygous mutants died shortly after implantation, and the
cells derived from pre-implantation embryos failed to grow. TRX(
/
)
cells are not available at this moment. As alternatives, we attempted
to inactivate endogenous TRX by treatment of cells with either an
antisense plasmid of human TRX or a specific inhibitor of TRX
reductase, DNCB (50). In Fig.
7A, we showed that
introduction of antisense TRX significantly reduced the amount of
endogenous TRX. In Fig. 7B, introduction of anti-TRX plasmid
or 1-chloro-2,4-dinitrobenzene, DNCB treatment (50 µM)
suppressed NF-
B-dependent luciferase gene activity by TNF
. We next investigated influence of knock-down treatment of TRX
system on I
B
degradation. As shown in Fig. 7C,
knock-down treatment of TRX cause the enhancement of TNF
-induced
I
B
degradation. This is a very good contrast to the reporter
assay data.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Requirement of TRX for the
NF- B transcriptional activity. HeLa cells
were plated and allowed to recover for 8-12 h. After transfection,
cells were incubated for 12 h and then treated by TNF (100 ng/ml). After 30 min for I B degradation assay or 12 h for
reporter assay, cell were harvested. In the case of DNCB treatment,
cells were treated for 30 min before TNF application. A,
amount of TRX of HeLa cells after introduction of sense or antisense
TRX expression vector. HeLa cells were transfected the mock expression
plasmid (lane 1), pcDNA3-TRX-wt, which means the
expression plasmid of wild type TRX (lane 2), or
pcDNA3-anti-TRX which means the expression plasmid of antisense TRX
(lane 3). Cell lysates (10 µg per lane) were resolved on a
15% SDS-PAGE and analyzed. TRX protein were visualized using the
11-mAb. B, regulation of TNF -elicited NF- B-mediated
gene expression by cellular TRX levels. HeLa cells were transiently
cotransfected with a 5× B-luciferase reporter gene plasmid (1 µg)
and expression vectors (1 µg) or pcDNA3 plasmid as control (1 µg) with 0.5 µg of pSV- -galactosidase. The results are the means
(mean ± S.D.) of three experiments (each done in duplicate) and
presented as fold increases in luciferase activity over the base line
seen with the mock transfectant without treatment. C,
regulation of TNF -elicited degradation of I B by cellular TRX
levels. Lane 1, pcDNA3 without TNF treatment;
lane 2, pcDNA3; lane 3, pcDNA3-wt-TRX;
lane 4, pcDNA3anti-TRX; lane 5, DCNB with
TNF treatment. Cell lysate (50 µg per lane) were resolved on a
10% SDS-PAGE and analyzed by the protocol described. I B protein
were visualized using an antibody raised against I B antibody
(C21).
|
|
 |
DISCUSSION |
In this paper, we demonstrate that TRX quickly translocates from
cytoplasm into nucleus in response to NF-
B activation stimuli such
as UVB irradiation and TNF
treatment, and TRX plays distinct roles
in the cytoplasm and in the nucleus on the signaling pathway to the
NF-
B-dependent transcription. In cytoplasm,
overexpression of TRX suppresses the degradation of I
B
; however,
in the nucleus TRX directly reduce the cysteine(s) of NF-
B and
allows the NF-
B-dependent gene expression.
Although post-translational modification such as phosphorylation and
dephosphorylation has been considered to be a principal regulatory
mechanism of protein function, recent studies collectively implicate
that additional mechanisms involving determination of intracellular
localization of protein are crucial components of signal transduction.
For example, in most cell types, NF-
B is present as a heterodimer
comprising p50 and p65 that are sequestered in the cytoplasm and are
associated with a member of the I
B family of inhibitory proteins.
When activation signals reach the I
B kinase complex, I
Bs are
phosphorylated by I
B kinases to be degraded and dissociated from
NF-
B, and this free NF-
B complex translocates from the cytoplasm
into the nucleus. Also in the case of mitogen-activated protein kinase
signaling, mitogen-activated protein kinase is activated in the
cytoplasm in response to extracellular signals and then translocates to
the nucleus. Thus, consideration of regulation of the transcription
factors with respect to cellular compartments may be an important issue
to be explored. Fig. 1 and Fig. 3 showed that TRX, which remains in the
cytoplasm, quickly translocates in the nucleus after UV irradiation
(Fig. 1, A and B), PMA (Fig. 3A), or
TNF
treatment (Fig. 3B). As this phenomenon can be
observed in HSC-1 cells from human skin cancer, HeLa cells from human
cervical cancer, and NIH3T3 cells from mouse fibroblast, nuclear
translocation of TRX seems to be a common phenomenon at least in
adhesive cell types. In addition, we reported that in mouse
Fe-nitrilotriacetic acid-induced renal tubular damage models, TRX
translocated into the nuclear compartment in response to generation of
ROI by Fe-nitrilotriacetic acid (51), and also in HeLa cells
H2O2 treatment induced TRX translocation (7).
As UV irradiation and TNF
and PMA treatment are shown to generate
ROIs in the cytoplasm (1, 2, 4), ROIs might trigger the nuclear
translocation of this redox-acting molecule, TRX. Indeed, pretreatment
with an antioxidant, N-acetyl-L-cysteine suppressed TNF
-elicited TRX
translocation.2 Although TRX
has no authentic nuclear localization signal sequence and details of
the translocation mechanism are under investigation, mutants of TRX,
TRX-C32S/C35S and TRX-(C62S/C69C/C73S), can locate in the nucleus (data
not shown). These data suggest that the redox status of TRX itself is
not the primary determinant of the translocation. Recently we (52) and
others (53) identified some proteins as TRX-binding proteins.
Regulation of association between TRX and these proteins may play an
important role in determining intracellular localization of TRX.
According to the multidimensional NMR study by Qin et al.
(44, 45), the enzymatically active center of TRX consists of a
"groove," and the oligopeptide from DNA-binding loop of NF-
B p50
fits the groove. As shown in Fig. 4, we demonstrated that TRX could
directly associate NF-
B p50 DNA-binding domain through its cysteines
in the catalytic domain in vitro. Structural analysis using
NMR technique and our in vitro experiment, using whole
recombinant molecules, demonstrates that TRX interplays directly with
NF-
B. Thus, the specificity of the molecular reaction between TRX
and NF-
B is an important issue to be discussed. GSH is the most
abundant small nonprotein thiol concentrated in the nucleus of
mammalian cells. However, in electrophoretic morbidity shift assay, TRX as a reducing molecule of NF-
B cannot be replaced by the glutathione system containing GSH, GSH reductase, and
NADPH.3 Thus, there seems to
be distinctions in the interaction between transcription factors and
reducing enzymes; NF-
B is a direct target of the TRX system but not
of the GSH system. Redox factor-1 (Ref-1), which is known as a nuclear
protein with augmenting DNA binding activity of AP-1 and recently shown
by us (8) as one of the target proteins of TRX, also has enhancing
activity of binding between NF-
B and DNA (54). At this moment, we
cannot neglect a possibility that TRX acts on NF-
B function via
other nuclear proteins such as Ref-1 and nucleoredoxin (55).
We can consider NF-
B transcriptional activation as two distinct
steps with respect to the cellular compartment. One step is I
B
degradation in the cytoplasm and following nuclear translocation of the
complex. Another step is DNA binding of the complex and transactivation
in the nucleus. Fig. 6 shows that overexpression of wild-type TRX,
which has catalase-like peroxide activity (56) and is also an electron
donor to TRX-dependent peroxide family (57, 58), in the
cytoplasm suppressed transcription by NF-
B system by scavenging ROI
as a second messenger of UVB and TNF
treatment. Indeed, as shown in
Fig. 7C, overexpression of TRX-wt suppressed degradation of
I
B
elicited by TNF
. Moreover, knock-down treatment of
endogenous TRX system using antisense plasmid against human TRX and
DNCB augmented I
B
degradation, whereas this treatment suppressed
B-dependent transcription. These evidences suggest that
signaling pathway to I
B degradation or phosphorylation are redox-sensitive. It is very interesting to know which molecule(s) is
(are) redox-sensitive, and we have data suggesting that TRX or
N-acetyl-L-cysteine-sensitive step is downstream
of TNF receptor associated factors and upstream of NF-
B-inducing
kinase.4 Thus, redox
regulation of NF-
B transcription by TRX has two distinct components.
One is cytoplasmic and the other is nucleic. If ROIs are generated and
act on the NF-
B system, ROIs might serve as part of messengers
mediating the release of the inhibitory subunit I
B from NF-
B.
Under such oxidizing conditions, reactive SH groups on NF-
B should
be oxidized. NF-
B or Rel family proteins share a characteristic
sequence motif with a cysteine and three arginine residues in the
DNA-binding loop, and these cysteines are susceptible to oxidation
(59-61). Dröge et al. (62) showed that oxidized
glutathione is important in the NF-
B activation signal cascade, and
elevated oxidized glutathione easily modulates the cysteine(s) of
NF-
B in vivo. Thus, the NF-
B complex liberated from
I
B may not be fully activated. It is necessary for oxidized cysteine(s) of NF-
B to be reduced for DNA binding.
We previously reported that various oxidative stresses including UVB
irradiation markedly induce TRX expression in cells (63-66). In
addition, we have data that TNF
treatment also induced TRX in HeLa
cells (data not shown). Induction of TRX can be observed no later than
6 h after oxidative stress. Induced TRX protein, which may
modulate redox state in the cytoplasm, could work as an effector of
negative feedback of NF-
B transcription. In contrast to the
induction, nuclear translocation of TRX is detected within 1 h of
cell response to stress. At the early phase of UV response, therefore,
endogenously expressed TRX could play an important role as a positive
regulator of NF-
B as well as AP-1.
In this paper, we showed that human TRX translocates into the nucleus
from the cytoplasm quickly in response to oxidative stress such as UV
irradiation and TNF
treatment. Thus, nuclear accumulation of TRX
might be an important process in the function of certain transcription
factors. In addition to the alteration of expression levels induced by
different kinds of cellular stress, differential subcellular
localization in response to the extracellular stimuli may constitute a
mechanism of the pleiotropic action of TRX in cells. Recently, it was
reported that E3330, a quinone derivative, selectively inhibited
NF-
B-mediated gene expression by suppressing NF-
B DNA binding
activity in the nucleus, without affecting any degradation of I
B
and translocation of NF-
B into the nucleus (67). This evidence
strongly suggests the existence of distinct regulation of NF-
B
function in the cytoplasm and in the nucleus.
 |
ACKNOWLEDGEMENTS |
We thank S. Yamaoka for technical advice; M. Matsui and S. Iwata for their useful discussions; W. Brown and R. Yamaguchi for review of the manuscript; N. Kikkawa for technical help;
and Y. Kanekiyo and E. Kobayashi for secretarial help. We also thank K. Fukuda for invaluable help.
 |
FOOTNOTES |
*
This work was supported in part by a grant-in-aid for
scientific research from the Ministry of Education, Science and Culture of Japan (to J. Y. and K. H.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Biological Responses, Institute for Virus Research, Kyoto University, 53 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto 606-01, Japan. Tel.: 81-75-751-4024; Fax: 81-75-761-5766; E-mail:
yodoi@virus.kyoto-u.ac.jp.
2
K. Hirota, unpublished observations.
3
T. Kawabe and J. Yodoi, unpublished observations.
4
J. Takeuchi and K. Hirota, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
TRX, thioredoxin;
ROI, reactive oxygen intermediate;
NF-
B, nuclear factor-
B;
AP-1, activating factor-1;
PMA, phorbol 12-myristate 13-acetate;
Ref-1, redox
factor-1;
PBS, phosphate-buffered saline;
DNCB, 1-chloro-2,4-dinitrobenzene;
TNF
, tumor necrosis factor-
;
PAGE, polyacrylamide gel electrophoresis;
wt, wild type;
mAb, monoclonal
antibody.
 |
REFERENCES |
| 1.
|
Pahl, H. L.,
and Baeuerle, P. A.
(1994)
BioEssays
16,
497-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Tyrrell, R. M.
(1996)
BioEssays
18,
139-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Su, B.,
Jacinto, E.,
Kallunki, T.,
Karin, M.,
and Ben-Neriah, Y.
(1994)
Cell
77,
727-736[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Stevenson, M. A.,
Pollock, S. S.,
Colman, C. N.,
and Calderwood, S. K.
(1994)
Cancer Res.
54,
12-15[Abstract/Free Full Text]
|
| 5.
|
Okamoto, T.,
Ogiwara, H.,
Hayashi, T.,
Mitsui, A.,
Kawabe, T.,
and Yodoi, J.
(1992)
Int. Immunol.
4,
811-819[Abstract/Free Full Text]
|
| 6.
|
Akamatsu, Y.,
Ohno, T.,
Hirota, K.,
Kagoshima, H.,
Yodoi, J.,
and Shigesada, K.
(1997)
J. Biol. Chem.
272,
14497-14500[Abstract/Free Full Text]
|
| 7.
|
Makino, Y.,
Okamoto, K.,
Yoshikawa, N.,
Aoshima, M.,
Hirota, K.,
Yodoi, J.,
Umesono, K.,
Makino, I.,
and Tanaka, H.
(1996)
J. Clin. Invest.
98,
2469-2477[Medline]
[Order article via Infotrieve]
|
| 8.
|
Hirota, K.,
Matsui, M.,
Iwata, S.,
Nishiyama, A.,
Mori, K.,
and Yodoi, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3633-3638[Abstract/Free Full Text]
|
| 9.
|
Holmgren, A.
(1985)
Annu. Rev. Biochem.
54,
237-271[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Holmgren, A.
(1989)
J. Biol. Chem.
264,
13963-13966[Free Full Text]
|
| 11.
|
Yodoi, J.,
and Uchiyama, T.
(1992)
Immunol. Today
13,
405-411[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Nakamura, H.,
Masutani, H.,
Tagaya, Y.,
Yamauchi, A.,
Inamoto, T.,
Nanbu, Y.,
Fujii, S.,
Ozawa, K.,
and Yodoi, J.
(1992)
Cancer (Phila.)
69,
2091-2097[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Tagaya, Y.,
Maeda, Y.,
Mitsui, A.,
Kondo, N.,
Masutani, H.,
Mamuro, J.,
Brown, N.,
Arai, K.-I.,
Yokota, T.,
Wakasugi, H.,
and Yodoi, J.
(1989)
EMBO J.
8,
757-764[Medline]
[Order article via Infotrieve]
|
| 14.
|
Nakamura, H.,
Nakamura, K.,
and Yodoi, J.
(1997)
Annu. Rev. Immunol.
15,
351-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Devary, Y.,
Rosette, C.,
DiDonato, J. A.,
and Karin, M.
(1993)
Science
261,
1442-1445[Abstract/Free Full Text]
|
| 16.
|
Dérijard, B.,
Hibi, M.,
Wu, I.-H.,
Barrett, T.,
Su, B.,
Deng, T.,
Karin, M.,
and Davis, R. J.
(1994)
Cell
76,
1025-1037[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Baeuerle, P. A.,
and Baltimore, D.
(1996)
Cell
87,
13-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Schenk, H.,
Klein, M.,
Erdbrügger, W.,
Dröge, W.,
and Schulze-Osthoff, K.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1672-1676[Abstract/Free Full Text]
|
| 19.
|
Sen, C. K.,
and Packer, L.
(1996)
FASEB J.
10,
709-720[Abstract]
|
| 20.
|
Meyer, M.,
Schreck, R.,
and Baeuerle, P. A.
(1993)
EMBO J.
12,
2005-2015[Medline]
[Order article via Infotrieve]
|
| 21.
|
Gómez del Arco, G.,
Martínez-Martínez, S.,
Calvo, V.,
Armesilla, A. L.,
and Rodondo, J. M.
(1996)
J. Biol. Chem.
271,
26335-26340[Abstract/Free Full Text]
|
| 22.
|
Régnier, C. H.,
Song, H. Y.,
Gao, X.,
Goeddel, D. V.,
Cao, Z.,
and Rothe, M.
(1997)
Cell
90,
373-383[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
DiDionate, J. A.,
Hayakawa, M.,
Rothwarf, D. M.,
Zandi, E.,
and Karin, M.
(1997)
Nature
388,
548-554[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Woronicz, J. D.,
Gao, X.,
Cao, Z.,
Rothe, M.,
and Goeddel, D. V.
(1997)
Science
278,
866-869[Abstract/Free Full Text]
|
| 25.
|
Zandi, E.,
Rothwart, D. M.,
Delhase, M.,
Hayakawa, M.,
and Karin, M.
(1997)
Cell
91,
243-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Catherine, H. R.,
Song, H. Y.,
Gao, X.,
Goeddel, D. V.,
Cao, Z.,
and Rothe, M.
(1997)
Cell
90,
373-383
|
| 27.
|
Yamaoka, S.,
Courtois, G.,
Bessia, C.,
Whiteside, S. T.,
Weil, R.,
Agou, F.,
Kirk, H. E.,
Kay, R. J.,
and Israël, A.
(1998)
Cell
93,
1231-1240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Stancovski, I.,
and Baltimore, D.
(1997)
Cell
91,
299-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Schreck, R.,
Albermann, K.,
and Baeuerle, P. A.
(1992)
Free Radic. Res. Commun.
17,
221-237[Medline]
[Order article via Infotrieve]
|
| 30.
|
Abate, C.,
Patel, L.,
Rauscher, F. J. D.,
and Curran, T.
(1990)
Science
249,
1157-1161[Abstract/Free Full Text]
|
| 31.
|
Myrset, A. H.,
Bostad, A.,
Nadege, J.,
Pierre-Noel, L.,
Toma, F.,
and Gabrielsen, O. S.
(1993)
EMBO J.
12,
4625-4633[Medline]
[Order article via Infotrieve]
|
| 32.
|
Jayaraman, L.,
Murthy, K. G.,
Zhu, C.,
Curran, T.,
Xanthoudakis, S.,
and Prives, C.
(1997)
Genes Dev.
11,
558-570[Abstract/Free Full Text]
|
| 33.
|
Makino, Y.,
Yoshikawa, N.,
Okamoto, K.,
Hirota, K.,
Yodoi, J.,
Makino, I.,
and Tanaka, H.
(1998)
J. Biol. Chem.
274,
3182-3188[Abstract/Free Full Text]
|
| 34.
|
Hayashi, S.-I.,
Hajiro-Nakanishi, K.,
Makino, Y.,
Eguchi, H.,
Yodoi, J.,
and Tanaka, H.
(1997)
Nucleic Acids Res.
25,
4035-4040[Abstract/Free Full Text]
|
| 35.
|
Ghosh, G.,
Duyne, G. V.,
Ghosh, S.,
and Sigler, P. B.
(1995)
Nature
373,
303-310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Müller, C. W.,
Rey, F. A.,
Sodeoka, M.,
Verdine, G. L.,
and Harrison, S. C.
(1995)
Nature
373,
311-317[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Toledano, M. B.,
and Leonard, W. J.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4328-4332[Abstract/Free Full Text]
|
| 38.
|
Matthews, J. R.,
Wakasugi, N.,
Virelizier, J. L.,
Yodoi, J.,
and Hay, R. T.
(1992)
Nucleic Acids Res.
20,
3821-3830[Abstract/Free Full Text]
|
| 39.
|
Hayashi, T.,
Ueno, Y.,
and Okamoto, T.
(1993)
J. Biol. Chem.
268,
11380-11388[Abstract/Free Full Text]
|
| 40.
|
Kondo, Y.,
and Aso, K.
(1981)
Br. J. Dermatol.
105,
125-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Sasada, T.,
Iwata, S.,
Sato, N.,
Kitaoka, Y.,
Hirota, K.,
Nakamura, K.,
Nishiyama, A.,
Taniguchi, Y.,
Takabayashi, A.,
and Yodoi, J.
(1996)
J. Clin. Invest.
97,
2268-2276[Medline]
[Order article via Infotrieve]
|
| 42.
|
Dignam, J. D.,
Lebovitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 43.
|
Baeuerle, P. A.,
and Henkel, T.
(1994)
Annu. Rev. Immunol.
12,
141-179[Medline]
[Order article via Infotrieve]
|
| 44.
|
Qin, J.,
Clore, G. M.,
Kennedy, W. M. P.,
Huth, J. R.,
and Gronenborn, A. M.
(1995)
Structure
3,
289-297[Medline]
[Order article via Infotrieve]
|
| 45.
|
Qin, J.,
Clore, G.,
Kennedy, W.,
Kuszewski, J.,
and Gronenborn, A.
(1996)
Structure
4,
613-620[Medline]
[Order article via Infotrieve]
|
| 46.
|
Oblong, J. E.,
Berggren, M.,
Gasdaska, P. Y.,
and Powis, G.
(1994)
J. Biol. Chem.
269,
11714-20[Abstract/Free Full Text]
|
| 47.
|
Chelsky, D.,
Ralph, R.,
and Jonak, G.
(1989)
Mol. Cell. Biol.
9,
2487-2492[Abstract/Free Full Text]
|
| 48.
|
Silver, P. A.
(1991)
Cell
64,
489-497[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Matsui, M.,
Oshima, M.,
Oshima, H.,
Takaku, K.,
Maruyama, T.,
Yodoi, J.,
and Taketo, M. M.
(1995)
Dev. Biol.
178,
179-185
|
| 50.
|
Arnér, E. S. J.,
Björnstedt, M.,
and Holmgren, A.
(1995)
J. Biol. Chem.
270,
3479-3482[Abstract/Free Full Text]
|
| 51.
|
Tanaka, T.,
Nishiyama, Y.,
Okada, K.,
Hirota, K.,
Matsui, M.,
Yodoi, J.,
Hiai, H.,
and Toyokuni, S.
(1997)
Lab. Invest.
77,
145-155[Medline]
[Order article via Infotrieve]
|
| 52.
|
Nishiyama, A.,
Ohno, T.,
Iwata, S.,
Matsui, M.,
Hirota, K.,
Masutani, H.,
Nakamura, H.,
and Yodoi, J.
(1999)
Immunol. Lett.
68,
155-159[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Saito, M.,
Nishitoh, H.,
Fujii, M.,
Takeda, K.,
Tobiume, K.,
Miyazono, K.,
and Ichijo, H.
(1998)
EMBO J.
17,
2596-2606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Mitomo, K.,
Nakayama, K.,
Fujimoto, K.,
Sun, X.,
Seki, S.,
and Yamamoto, K.
(1994)
Gene (Amst.)
145,
197-203[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Kurooka, H.,
Kato, K.,
Minoguchi, S.,
Takahashi, Y.,
Ikeda, J.,
Habu, S.,
Osawa, N.,
Buchberg, A. M.,
Moriwaki, K.,
Shisa, H.,
and Honjo, T.
(1997)
Genomics
39,
331-339[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Mitsui, A.,
Hirakawa, T.,
and Yodoi, J.
(1992)
Biochem. Biophys. Res. Commun.
186,
1220-1226[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Chae, H. Z.,
Robison, K.,
Poole, L. B.,
Church, G.,
Storz, G.,
and Rhee, S. G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7017-7021[Abstract/Free Full Text]
|
| 58.
|
Kang, S. W.,
Chae, H. Z.,
Seo, M. S.,
Kim, K.,
Baines, I. C.,
and Rhee, S. G.
(1998)
J. Biol. Chem.
273,
6297-6302[Abstract/Free Full Text]
|
| 59.
|
Rokutan, K.,
Johnston, R. B., Jr.,
and Kawai, K.
(1994)
Am. J. Physiol.
266,
G247-G254[Abstract/Free Full Text]
|
| 60.
|
Schuppe, I.,
Moldeus, P.,
and Cotgreave, I. A.
(1992)
Biochem. Pharmacol.
44,
1757-1764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Matthews, J. R.,
Botting, C. H.,
Panico, M.,
Morris, H. R.,
and Hay, R. T.
(1996)
Nucleic Acids Res.
24,
2236-2242[Abstract/Free Full Text]
|
| 62.
|
Dröge, W.,
Schulze-Osthoff, K.,
Mihm, S.,
Galter, D.,
Schenk, H.,
Eck, H.-P.,
Roth, S.,
and Gmünder, H.
(1994)
FASEB J.
8,
1131-1138[Abstract]
|
| 63.
|
Nakamura, H.,
Matsuda, M.,
Furuke, K.,
Kitaoka, Y.,
Iwata, S.,
Toda, K.,
Inamoto, T.,
Yamaoka, Y.,
Ozawa, K.,
and Yodoi, J.
(1994)
Immunol. Lett.
42,
75-80[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Sachi, Y.,
Hirota, K.,
Masutani, H.,
Toda, K.-I.,
Okamoto, T.,
Takigawa, M.,
and Yodoi, J.
(1995)
Immunol. Lett.
44,
189-193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Hori, K.,
Katayama, M.,
Sato, N.,
Ishii, K.,
Waga, S.,
and Yodoi, J.
(1994)
Brain Res.
652,
304-310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Taniguchi, Y.,
Taniguchi-Ueda, Y.,
Mori, K.,
and Yodoi, J.
(1996)
Nucleic Acids Res.
24,
2746-2752[Abstract/Free Full Text]
|
| 67.
|
Hiramoto, M.,
Shimizu, N.,
Sugimoto, K.,
Tang, J.,
Kawakami, Y.,
Ito, M.,
Aizawa, S.,
Tanaka, H.,
Makino, I.,
and Handa, H.
(1998)
J. Immunol.
160,
810-819[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.